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The minimal clinically important difference (MCID) 
is a widely used concept to interpret the meaning of 
health-related quality of life (HRQoL) score changes. 
However, to give a greater sense of the meaning of score 
change across a wider spectrum of score changes, we 
propose a new concept of ‘2MCID’. This represents a 
score change of twice the MCID. This approach, novel 
in dermatology, has been used in other areas (1, 2) and 
highlights therapies that reach this higher change thres-
hold. We hypothesise that this method would better dis-
criminate between the efficacy of interventions to help 
guide clinical judgement and patient progress. 
HRQoL outcome measures capture several aspects 
of a patient’s overall well-being (3). Such measures are 
increasingly being implemented in interventional studies 
alongside clinical objective parameters as important 
contributors towards morbidity and mortality data (4). 
Reports of studies often include HRQoL data citing 
statistical differences pre- and post-intervention, though 
statistically significant changes may not be reflective of 
meaningful change in HRQoL, particularly within large 
sample sizes which may produce statistically significant 
change despite the change being small (5).
The MCID is the minimum difference needed for a 
patient to perceive the change as beneficial (6) and may 
be used to determine whether a medical intervention 
improves patient perceived outcomes. Factors to consi-
der when calculating the MCID for a particular outcome 
include: patient baseline severity, particular disease or 
condition, patient demographics and treatment. There is 
no consensus on the best methodology for calculating 
the MCID (7), and values may therefore differ. Despite 
these limitations, it is still more useful for clinicians to 
assess intervention effectiveness based on the patient’s 
perspective, rather than solely on statistical significance. 
The most commonly utilized quality of life (QoL) tool 
in psoriasis trials is the Dermatology Life Quality Index 
(DLQI), with an MCID of 4 points (8, 9). During this 
systematic review we noted that multiple MCID could 
provide a further aid to the results’ interpretation: we 
felt this novel concept deserved further exploration. We 
have therefore applied the 2MCID concept to data from 
that review (8).
METHODS
A systematic review was presented by Ali et al. (8). We have 
introduced the concept of 2MCID to that dataset (i.e. DLQI score 
change of at least 8) to demonstrate comparative efficacy between 
interventions.
RESULTS
A total of 100 trials were identified by the systematic 
review, covering diverse interventions. As the DLQI 
was the most commonly used QoL measure (83% of 
studies), the 2MCID concept was tested on interventions 
with documented DLQI scores. Fig. 1 summarises all the 
interventions that met the different MCID thresholds.
For topical treatments, clobetasol 0.05% spray showed 
the greatest improvement at 4 weeks (2MCID, 8 point im-
provement), followed by calcipotriol plus betamethasone 
at 8 weeks (6.4 points). These changes are comparable 
to ustekinumab 90 mg at 12 weeks (mean 2MCID (8 
point) improvement) and ciclosporin 3–5 mg/kg at 12 
weeks (6.6 point improvement). No other topical therapy 
reached 2MCID. However, it is important to consider the 
context of baseline psoriasis severity, treatment duration 
and long-term QoL maintenance. 
Methotrexate 15 mg at 16 weeks was the only systemic 
intervention over the 2MCID threshold (8.7 points). This 
was comparable to several biologics, including etaner-
cept 50 mg at 24 weeks and ustekinumab 90 mg at 12 
weeks (8.7 points). 
Infliximab 5 mg/kg at 16 weeks and secukinumab 300 
mg at 12 weeks demonstrated the largest improvement 
in DLQI score of a mean of 11.4 (>2MCID), just short 
of 3MCID. Amongst other interventions, an energy-res-
tricted diet with immunosuppressive therapy at 24 weeks 
recorded DLQI improvement of 14.4 (3MCID). DLQI at 
12 weeks improved by 11.2 (>2MCID) with PUVAsol 
0.6 mg/kg + isotretinoin 0.5 mg/kg: for PUVAsol alone, 
DLQI improvement was 6.8.
For studies with treatment endpoint and assessment 
at 12 weeks, the interventions with the greatest mean 
DLQI impact in each category were secukinumab 300 mg 
(2MCID, 11.4 points), ciclosporin 3–5 mg/kg (1MCID, 
6.6 points), PUVAsol 0.6 mg/kg+isotretinoin 0.5 mg/
kg (2MCID, 11.2 points), Liquor Carbonis Distillate 
solution 15% (1MCID, 5.8 points) and educational pro-
gramme (1MCID, 4 points). 
DISCUSSION
Previously, Leaf & Goldfarb (1) described the impact of 
erythropoiesis stimulating agents on HRQoL using Short-
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Form 36 and The Kidney Disease Questionnaire. 
However, the authors only infrequently arbitrarily 
refer to score changes using multiples of MCID 
without formal concept utilization. Similarly, 
Jones et al. (2) equate a change of ‘twice the 
MCID’ to a ‘large benefit’ when comparing active 
treatments for COPD against placebo using the 
St. George’s Respiratory Questionnaire. Neither 
study formally explored or stratified results.
Although score banding descriptors can be 
used (10) to describe patient numbers within 
score bands pre- and post-intervention, a method 
is needed to discriminate between the extent of 
the effect of interventions on QoL. The concept 
of ‘multiple-MCID’ could add meaning to score 
change when comparing therapies, or when com-
paring results across different QoL instruments as 
a ‘unit of change’. 2MCID appears to be a practi-
cal threshold providing a meaningful ‘hurdle’ that 
developers of new interventions might strive to 
achieve. In the systematic review analysis, only 
one data set from 83 RCTs demonstrated a change 
of 3MCID, indicating that a 3MCID ‘hurdle’ 
would be a difficult and impractical threshold.
This ‘pilot study’ of the ‘multiple-MCID’ con-
cept demonstrates the potential benefit of compa-
ring the extent of impact of different categories of 
interventions on QoL and interpreting change over 
time. We have demonstrated that some systemic 
interventions may impact QoL to the same extent 
as certain biologic treatments. Similarly, certain 
topical treatments may be as efficacious as syste-
mic alternatives. However, the systematic review 
dataset is not homogenous and often patients have 
different baseline severities. Although MCID 
values are applied across a spectrum of scores 
in interpreting change in scores of a measure, in 
reality the MCID score value may be different if 
the score change is at the lower or upper end of 
a HRQoL measure score range. This criticism of 
the concept of MCID requires further investiga-
tion, possibly through meta-regression where 
the magnitude of effect on DLQI is regressed 
on baseline severity. The 2MCID concept may 
be too simplistic: ideally the identification and 
calculation of a multiple-MCID score should be 
based on prospective research based on patient 
assessment of a higher level of change, using an 
anchor question based on, say, “Major clinically 
important difference”. 
Despite these reservations we believe ‘multiple-
MCID’ provides additional meaningful informa-
tion on clinical improvement and may be of value 
to clinicians, patients and the pharmaceutical 
industry. Medications that meet the ‘2MCID’ 
minimum threshold might be more readily appro-
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Yinxieling formula at 8 weeks
XP-828L (Dermylex) 400 mg at 8 weeks
Voclosporin 0.4 mg/kg at 12 weeks
Voclosporin 0.3 mg/kg at 12 weeks
Voclosporin 0.2 mg/kg at 12 weeks
Voclosporin (ISA247) 1.5 mg/kg at 12 weeks
Voclosporin (ISA247) 0.5 mg/kg at 12 weeks
Ustekinumab 90 mg at 24 weeks
Ustekinumab 90 mg at 12 weeks
Ustekinumab 45 mg at 24 weeks
Ustekinumab 45 mg at 12 weeks
Ustekinumab 45-90 mg with immediate methotrexate withdrawal at 16 
weeks
Triamcinolone Acetonide 0.1% at 8 weeks
Tofacitinib 5 mg at 12 weeks
Tofacitinib 2 mg at 12 weeks
Tofacitinib 15 mg at 12 weeks
Sulphurous Mineral Waters Spray at 2 weeks
Secukinumab 300 mg at 12 weeks
Secukinumab 150 mg at 12 weeks
PUVAsol 0.6 mg/kg at 12 weeks
PUVAsol 0.6 mg/kg & Isotretinoin 0.5 mg/kg at 12 weeks
Placebo + nUVB at 24 weeks (compared with Methotrexate + nUVB)
Mometasone furoate 0.1% at 1 week
Mometasone furoate 0.1% + salicylic acid 5% at 1 week
Mindfulness-based cognitive therapy at 8 weeks
Methotrexate 7.5 mg at 16 weeks
Methotrexate 7.5 mg at 12 weeks
Methotrexate 15 mg at 16 weeks
Methotrexate 15 mg + nUVB at 24 weeks
Methotrexate + Folic Acid 5 mg at 12 weeks
Methotrexate (without Folic Acid) at 12 weeks
Low energy diet at 16 weeks
Low Dose Cytokines at 12 weeks
Liraglutide 1.8 mg at 8 weeks
Leflunomide 20 mg at 24 weeks
LCD Solution 15% at 12 weeks
Ixekizumab 75 mg at 8 weeks
Ixekizumab 25 mg at 8 weeks
Ixekizumab 150 mg at 8 weeks
Itolizumab 1.6 mg/kg at 12 weeks
Interdisciplinary dermatological and psychiatric care for psoriasis at 24 
weeks
Infliximab 5 mg/kg at 50 weeks
Infliximab 5 mg/kg at 24 weeks
Infliximab 5 mg/kg at 16 weeks
Infliximab 5 mg/kg at 14 weeks
Infliximab 5 mg/kg at 10 weeks
Infliximab 5 mg/kg at 100 weeks
Infliximab 3 mg/kg at 50 weeks
Infliximab 3 mg/kg at 10 weeks
Etanercept 50 mg at 54 weeks
Etanercept 50 mg at 24 weeks
Etanercept 50 mg at 12 weeks
Etanercept 50 mg + nUVB at 12 weeks (Patients who did not achieve 
PASI 90 after 12 weeks of Etanercept)
Etanercept 25 mg at 54 weeks
Etanercept 25 mg at 12 weeks
Etanercept 25 mg + continued methotrexate treatment
Etanercept 100 mg at 12 weeks
Etanercept + tapered methotrexate
Energy-restricted diet at 24 weeks
Efalizumab 1 mg/kg at 12 weeks
Educational Programme at 12 weeks
Educational Nursing Intervention at 6 weeks
Dermatological care for psoriasis at 24 weeks
DAB389IL-2 (5-15 mg/kg) at 4 weeks
Clobetasol Spray 0.05% at 4 weeks
Clobetasol Foam 0.05% at 2 weeks
Clobetasol Cream 0.05% at 2 weeks
Ciclosporin 3-5 mg/kg at 12 weeks
Chondroitin sulphate 800 mg at 12 weeks
Certolizumab 400 mg at 24 weeks
Certolizumab 400 mg at 12 weeks
Certolizumab 200 mg at 24 weeks
Certolizumab 200 mg at 12 weeks
Calcipotriol betamethasone at 8 weeks
Calcipotriol betamethasone at 4 weeks
Calcipotriol at 4 weeks
Calcipotriol 50 mcg/g at 8 weeks
Calcipotriene 0.005% at 12 weeks
Brodalumab 70 mg at 12 weeks
Brodalumab 280 mg at 12 weeks
Brodalumab 210 mg at 12 weeks
Brodalumab 140 mg at 12 weeks
Briakinumab 200 mg at 12 weeks
Briakinumab 100 mg at 40 weeks
Betamethasone valerate dressing at 4 weeks
Betamethasone at 8 weeks
Auricular Therapy + Yinxieling formula at 8 weeks
Apremilast 30 mg at 16 weeks
Apremilast 20 mg at 16 weeks
Apremilast 10 mg at 8 weeks
Aloe Vera 70% at 8 weeks
Alefacept 15 mg at 16 weeks
Alefacept 15 mg at 12 weeks
Alefacept 10 mg at 12 weeks
Adalimumab 80 mg at 24 weeks
Adalimumab 40 mg at 24 weeks
Adalimumab 40 mg at 16 weeks
Adalimumab 40 mg at 12 weeks
Adalimumab 40 mg + vehicle at 16 weeks
Adalimumab 40 mg + calcipotriol betamethasone at 16 weeks
Change in DLQI score from baseline
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Fig. 1. Mean Dermatology Life Quality Index (DLQI) score change in 83 
clinical trials for psoriasis (8), showing those interventions that reached 1 
minimal clinically important difference (MCID) and 2 MCID score change.
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ved by pharmaceutical regulatory authorities and health 
technology assessment agencies. This concept may also 
enable researchers to better distinguish between inter-
ventions and comparators in trials, potentially improving 
patients’ access to the most effective new medicines. 
Prospective longitudinal studies could aim to prove 
the usefulness of the concept before implementing it 
more widely. Further work is required before this novel 
concept is adopted in treatment decision-making and in 
reimbursement appraisals.
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